XARELTO®: Coronary artery disease (CAD) and peripheral artery disease (PAD) treatment

In the COMPASS trial, the XARELTO® vascular dose* significantly reduced a composite of CV death, MI, and stroke in patients with CAD and/or PAD.1

The XARELTO® vascular dose* = XARELTO® 2.5 mg twice daily plus aspirin (75 mg to 100 mg) once daily.2

*Patients with chronic coronary syndromes (chronic CAD) and in sinus rhythm. Recommended treatment options for dual antithrombotic therapy in combination with aspirin include rivaroxaban, clopidogrel, prasugrel, and ticagrelor.

Not adjusted for multiplicity.

CAD = coronary artery disease; CV = cardiovascular; DOAC = direct oral anticoagulant; ESC = European Society of Cardiology; MI = myocardial infarction; PAD = peripheral artery disease.

Need Help?